AMGNAmgenRunning, no new patients
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 163 (final count)
- Started
- Sep 12, 2024
- Main results expected
- Dec 14, 2026
- Fully finished
- Dec 14, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Area Under the Serum Concentration-time Curve (AUC) From Time 0 to 21 Days (AUC21d) Following the First Dose
Measured over: 21 days
AUC at Steady State Between Week 16 and Week 19 (AUCtau_ss)
Measured over: Weeks 16-19
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06430866 · record last updated 2026-04-01 · checked 2026-11-09 15:47 UTC